

ASX ANNOUNCEMENT

CELLMID INVESTOR BRIEFING

SYDNEY, Thursday, 21 July 2016: Cellmid Limited (ASX: CDY) is pleased to advise that it has closed a very successful 2016 financial year with significant sales growth and major milestones achieved during the period.

Cellmid will be hosting a conference call to brief the market on its operations, sales results and international activities on Wednesday, 27 July 2016 at 9:00am (AEST).

The Appendix 4C for the Consolidated Entity with cash flow information for the three months ending 30 June 2016 is expected to be available prior to the briefing. Cellmid CEO, Maria Halasz, will be discussing operations, marketing and sales activities in Australia and Japan and will outline planned activities in the US following the recently announced distribution partnership with Colour Collective.

To join the conference call, please dial via the numbers below shortly before the scheduled timeslot. **Conference ID: 737 683** – please provide this ID when joining the call. Australian participant dial-in numbers:

Local: **+61 2 9007 8048**
Alt. Local: **+61 7 3145 4005**

International participant dial-in numbers:


USA/Canada Toll Free: **1855 624 0077**
UK Toll Free: **0800 051 1453**
Japan Toll Free: **0066 3386 8000**
Hong Kong Toll Free: **800 968 273**
Singapore Toll Free: **800 101 2702**

For countries not listed, please dial the Australian participant local number listed above. To ask a question during the live Q&A session, participants will need to **press * (star) followed by 1 ("*, 1")** on their telephone keypad to enter the Q&A queue.

End

Contact:

Maria Halasz, CEO
T +612 9221 6830

 @mariahalasz

Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences company with lead programs in multiple disease indications. The Company, through its wholly owned subsidiaries, develops and markets innovative novel therapies and diagnostic tests for fibrotic diseases, cancer, ischemic diseases of the heart and hair loss. Cellmid holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) and FGF5 globally. Through its Advangen business, Cellmid sells its FGF5 inhibitor hair growth products in Australia and Japan, and expanding distribution in other territories. For further information, please see www.cellmid.com.au and www.evolisproducts.com.au.

Advangen Limited - Cellmid's Consumer Health Division

In 2013 Cellmid acquired Advangen Inc. (Japan), the owner of a range of FGF5 hair growth technologies and became the only company globally with an FGF5 inhibitor hair growth product range on the market. Cellmid has continued innovation and product development and filed a number of new patent applications covering several hair growth agents including midkine and a group of novel FGF5 inhibitors. In addition to distribution in Australia and Japan the Company is actively expanding into other markets such as the USA, Asia and Europe.

Forward-Looking Statements

This press release may include forward-looking statements that relate to future events and/or future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise